Halozyme Therapeutic (HALO)

$71.48 +0.75 (1.06%)
Market Cap 8.39B
Revenue (ttm) 1.40B
Net Income (ttm) 316.89M
EPS (ttm) N/A
PE Ratio 16.91
Forward PE 9.49
Profit Margin 22.69%
Debt to Equity Ratio 9.76
Volume 1,317,600
Avg Vol 1,645,092
Day's Range N/A - N/A
Shares Out 118.61M
Stochastic %K 88%
Beta 0.88
Analysts Sell
Price Target $83.90

Company Profile

Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 794 8889
Fax: 858 704 8311
Address:
12390 El Camino Real, San Diego, United States
Sean29md
Sean29md Jun. 9 at 8:17 PM
$HALO Halozyme’s new CFO, “Mr. Snellgrove led investor relations at Johnson & Johnson, where he oversaw global investor engagement and helped strengthen corporate messaging, analyst relationships, and market performance.” Welcome aboard! Halzoyme is in need of a major shake up in its IR. One of the biggest contributors to extremely low PEG and forward PE valuations has been an inability to attract non-institutional investors. Prices in modern markets are determined by the marginal buyers. Halozyme is almost 100% institutionally owned. I hope you and Helen take the time to appear on CNBC, bloomberg, investor YouTube channels and Podcasts. It would also help a lot if you buy some shares yourself in the open markets. We look forward to seeing a meaningful improvement in Halozyme’s valuations under your leadership. https://halozyme.com/leadership/darren-snellgrove/
0 · Reply
AlphaTrader8
AlphaTrader8 Jun. 9 at 4:09 PM
$INTC rotation out of Tech to Value $HALO Market stat 4% down Nasdaq on Friday 6/5/2026 Market takes out Friday’s Low Speculation Trades In Ai Trade are leaving ramp up AI stocks $QQQ $SPY $NVDA
0 · Reply
1AMBITIOUSSAVAGE
1AMBITIOUSSAVAGE Jun. 5 at 4:57 PM
$ARGX 👏🏼 LFG $HALO $SPCE $IBM Profits to VSEE 👀
0 · Reply
JR603
JR603 Jun. 5 at 1:44 PM
$HALO What's the latest with the Merck patent suit?
0 · Reply
Avocado_smash
Avocado_smash Jun. 5 at 12:54 PM
$HALO Bullish, getting stronger.
0 · Reply
Doozio
Doozio Jun. 4 at 2:08 PM
$XBI may da $HALO protect YO while DAVE drops his NUTX on da 🐑 n yo SEZL ONTA 🐒🍌🧠⏰♾️
0 · Reply
French_Vibe
French_Vibe Jun. 3 at 1:21 PM
$HALO I added at $66. With a "PEG" of 0.5 (based on FCF), it's one of the most interesting investments in biotech.
0 · Reply
Sean29md
Sean29md Jun. 2 at 2:17 PM
$HALO EPS Next Y $9.93 EPS growth this year 95.41% EPS growth next 5 years 39.10% Gross Margin 76.93% All this trading at a forward PE of 6.66 and PEG of 0.17 https://finviz.com/stock?t=HALO&ty=c&ta=1&p=d It is not only irresponsible for the insiders not to buy shares, it is also idiotic to pass up on such amazing value and growth.
1 · Reply
Makingmillions192
Makingmillions192 Jun. 2 at 2:10 PM
$HALO $LEXX $LLY $NVO This feels like they are still marketing to retail - but Rich literally lit that bridge on fire last year. They “have an MTA” and “have early stage convos with other pharma companies” Why are they still coming to the retail well? Why aren’t the private placement financiers supporting the price? These guys need to smarten up.
0 · Reply
Makingmillions192
Makingmillions192 Jun. 2 at 1:30 PM
$LEXX While Lexaria can be considered an industry unicorn – a pure play delivery technology company - Halozyme Therapeutics $HALO offers the closest comparable business model. They own their own drug delivery platform and partners with major pharma companies, but they are not focused on the lucrative and rapidly growing GLP-1 space. The dominant players in GLP-1, including Novo Nordisk $NVO and Eli Lilly $LLY are investing heavily in developing oral delivery GLP-1s, but not the delivery mechanism itself. This distinction is what sets Lexaria apart; it’s positioned as a potential add-on technology across multiple existing therapies, rather than a direct competitor to any single drug. CEO Richard Christopher believes that this positioning could prove highly valuable. We feel we have a home run here. https://www.theglobeandmail.com/investing/markets/stocks/GLD-A/pressreleases/2208563/lexaria-bioscience-finds-its-niche-in-the-lucrative-glp-1-market/
0 · Reply
Latest News on HALO
Halozyme price target lowered to $93 from $96 at Morgan Stanley

2026-05-12T16:13:22.000Z - 4 weeks ago

Halozyme price target lowered to $93 from $96 at Morgan Stanley

Halozyme Therapeutics Earnings Call Transcript: Q1 2026

May 11, 2026, 4:30 PM EDT - 4 weeks ago

Halozyme Therapeutics Earnings Call Transcript: Q1 2026

Halozyme Therapeutics Earnings release: Q1 2026

May 11, 2026, 4:30 PM EDT - 4 weeks ago

Halozyme Therapeutics Earnings release: Q1 2026

Halozyme Therapeutics Quarterly report: Q1 2026

May 11, 2026, 4:30 PM EDT - 4 weeks ago

Halozyme Therapeutics Quarterly report: Q1 2026

Halozyme Therapeutics Slides: Q1 2026

May 11, 2026, 4:30 PM EDT - 4 weeks ago

Halozyme Therapeutics Slides: Q1 2026

HALOZYME REPORTS FIRST QUARTER 2026 RESULTS AND REITERATES 2026 FINANCIAL GUIDANCE

May 11, 2026, 4:01 PM EDT - 4 weeks ago

HALOZYME REPORTS FIRST QUARTER 2026 RESULTS AND REITERATES 2026 FINANCIAL GUIDANCE

Halozyme announces global collaboration and license agreement with GSK

2026-05-07T19:48:39.000Z - 4 weeks ago

Halozyme announces global collaboration and license agreement with GSK

GSK

Halozyme Announces Global Collaboration and License Agreement with GSK to Develop Subcutaneous Formulations of Multiple Promising Oncology Targets

May 7, 2026, 9:00 AM EDT - 4 weeks ago

Halozyme Announces Global Collaboration and License Agreement with GSK to Develop Subcutaneous Formulations of Multiple Promising Oncology Targets

Halozyme licenses Hypercon technology to Oruka Therapeutics in psoriasis

2026-05-07T06:12:19.000Z - 4 weeks ago

Halozyme licenses Hypercon technology to Oruka Therapeutics in psoriasis

ORKA

Halozyme and Oruka Announce Global Collaboration and License Agreement to Develop ORKA-001 with Hypercon™ Technology

May 6, 2026, 8:00 AM EDT - 4 weeks ago

Halozyme and Oruka Announce Global Collaboration and License Agreement to Develop ORKA-001 with Hypercon™ Technology

ORKA

Halozyme Therapeutics Transcript: AGM 2026

May 5, 2026, 12:00 PM EDT - 5 weeks ago

Halozyme Therapeutics Transcript: AGM 2026

Halozyme to Report First Quarter 2026 Financial and Operating Results

Apr 30, 2026, 4:30 PM EDT - 5 weeks ago

Halozyme to Report First Quarter 2026 Financial and Operating Results

Halozyme names Darren Snellgrove as CFO

2026-04-30T17:01:40.000Z - 5 weeks ago

Halozyme names Darren Snellgrove as CFO

JNJ

Halozyme Appoints Darren Snellgrove as Chief Financial Officer

Apr 30, 2026, 8:00 AM EDT - 5 weeks ago

Halozyme Appoints Darren Snellgrove as Chief Financial Officer

Halozyme price target raised to $95 from $90 at H.C. Wainwright

2026-04-29T10:25:50.000Z - 5 weeks ago

Halozyme price target raised to $95 from $90 at H.C. Wainwright

Halozyme price target raised to $96 from $94 at Morgan Stanley

2026-04-21T12:51:13.000Z - 7 weeks ago

Halozyme price target raised to $96 from $94 at Morgan Stanley

Halozyme enters global global collaboration and license agreement with Vertex

2026-04-07T12:23:24.000Z - 2 months ago

Halozyme enters global global collaboration and license agreement with Vertex

VRTX

Halozyme Announces Global Collaboration and License Agreement with Vertex Pharmaceuticals for Hypercon™ Technology

Apr 7, 2026, 8:00 AM EDT - 2 months ago

Halozyme Announces Global Collaboration and License Agreement with Vertex Pharmaceuticals for Hypercon™ Technology

Halozyme Therapeutics Proxy statement: Proxy filing

Mar 23, 2026, 8:00 AM EDT - 2 months ago

Halozyme Therapeutics Proxy statement: Proxy filing

Halozyme Therapeutics Proxy statement: Proxy filing

Mar 23, 2026, 8:00 AM EDT - 2 months ago

Halozyme Therapeutics Proxy statement: Proxy filing

Halozyme names David Ramsay as Interim CFO

2026-03-12T12:38:03.000Z - 3 months ago

Halozyme names David Ramsay as Interim CFO

Halozyme Appoints David Ramsay as Interim Chief Financial Officer

Mar 12, 2026, 8:30 AM EDT - 3 months ago

Halozyme Appoints David Ramsay as Interim Chief Financial Officer

Halozyme Therapeutics Transcript: The Citizens Life Sciences Conference 2026

Mar 11, 2026, 10:45 AM EDT - 3 months ago

Halozyme Therapeutics Transcript: The Citizens Life Sciences Conference 2026

Halozyme Therapeutics Transcript: Leerink Global Healthcare Conference 2026

Mar 10, 2026, 1:00 PM EDT - 3 months ago

Halozyme Therapeutics Transcript: Leerink Global Healthcare Conference 2026

U.S. FDA Approves TECVAYLI® in Combination with DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma

Mar 6, 2026, 8:00 AM EST - 3 months ago

U.S. FDA Approves TECVAYLI® in Combination with DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma

Halozyme Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Mar 3, 2026, 11:10 AM EST - 3 months ago

Halozyme Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Halozyme to Participate in Upcoming Investor Conferences

Feb 25, 2026, 8:30 AM EST - 3 months ago

Halozyme to Participate in Upcoming Investor Conferences

Halozyme price target raised to $94 from $78 at Morgan Stanley

2026-02-19T13:43:22.000Z - 3 months ago

Halozyme price target raised to $94 from $78 at Morgan Stanley

Halozyme price target raised to $90 from $75 at Benchmark

2026-02-19T13:36:39.000Z - 3 months ago

Halozyme price target raised to $90 from $75 at Benchmark

Halozyme price target raised to $75 from $65 at Wells Fargo

2026-02-19T11:32:57.000Z - 3 months ago

Halozyme price target raised to $75 from $65 at Wells Fargo

Halozyme Therapeutics Earnings Call Transcript: Q4 2025

Feb 17, 2026, 4:30 PM EST - 4 months ago

Halozyme Therapeutics Earnings Call Transcript: Q4 2025

Halozyme Therapeutics Annual report: Q4 2025

Feb 17, 2026, 4:30 PM EST - 4 months ago

Halozyme Therapeutics Annual report: Q4 2025

Halozyme Therapeutics Earnings release: Q4 2025

Feb 17, 2026, 4:30 PM EST - 4 months ago

Halozyme Therapeutics Earnings release: Q4 2025

Halozyme Therapeutics Slides: Q4 2025

Feb 17, 2026, 4:30 PM EST - 4 months ago

Halozyme Therapeutics Slides: Q4 2025

Halozyme reports Q4 EPS 24c vs. $1.26 last year

2026-02-17T21:05:28.000Z - 4 months ago

Halozyme reports Q4 EPS 24c vs. $1.26 last year

HALOZYME REPORTS FULL YEAR 2025 RECORD REVENUE OF $1.4 BILLION AND REITERATES STRONG 2026 FINANCIAL GUIDANCE

Feb 17, 2026, 4:01 PM EST - 4 months ago

HALOZYME REPORTS FULL YEAR 2025 RECORD REVENUE OF $1.4 BILLION AND REITERATES STRONG 2026 FINANCIAL GUIDANCE

Halozyme to Report Fourth Quarter and Full Year 2025 Financial and Operating Results

Feb 10, 2026, 4:05 PM EST - 4 months ago

Halozyme to Report Fourth Quarter and Full Year 2025 Financial and Operating Results

Halozyme Therapeutics Transcript: Investor update

Jan 28, 2026, 8:30 AM EST - 4 months ago

Halozyme Therapeutics Transcript: Investor update

Halozyme Therapeutics Press release: Investor update

Jan 28, 2026, 8:30 AM EST - 4 months ago

Halozyme Therapeutics Press release: Investor update

Halozyme Therapeutics Slides: Investor update

Jan 28, 2026, 8:30 AM EST - 4 months ago

Halozyme Therapeutics Slides: Investor update

Halozyme Raises 2025 Revenue Estimates, Raises 2026 and Multi-Year Financial Guidance

Jan 28, 2026, 6:30 AM EST - 4 months ago

Halozyme Raises 2025 Revenue Estimates, Raises 2026 and Multi-Year Financial Guidance

Halozyme to Host Investor Conference Call to Provide Updated Financial Guidance and Business Update

Jan 20, 2026, 4:05 PM EST - 5 months ago

Halozyme to Host Investor Conference Call to Provide Updated Financial Guidance and Business Update

Leerink views ‘major deal’ on Entyvio as positive for Halozyme

2026-01-08T18:40:15.000Z - 5 months ago

Leerink views ‘major deal’ on Entyvio as positive for Halozyme

TAK

Halozyme price target raised to $90 from $79 at TD Cowen

2026-01-08T14:43:27.000Z - 5 months ago

Halozyme price target raised to $90 from $79 at TD Cowen

Halozyme Announces Global Collaboration and License Agreement with Takeda to Develop and Commercialize Vedolizumab with ENHANZE®

Jan 8, 2026, 8:00 AM EST - 5 months ago

Halozyme Announces Global Collaboration and License Agreement with Takeda to Develop and Commercialize Vedolizumab with ENHANZE®

Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE® for Obesity

Jan 5, 2026, 7:00 AM EST - 5 months ago

Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE® for Obesity

SKYE

U.S. FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Co-Formulated with ENHANZE® for the Treatment of Advanced EGFR-mutated Non-Small Cell Lung Cancer

Dec 18, 2025, 7:00 AM EST - 6 months ago

U.S. FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Co-Formulated with ENHANZE® for the Treatment of Advanced EGFR-mutated Non-Small Cell Lung Cancer

Jim Lang Elected to Halozyme's Board of Directors

Dec 8, 2025, 4:05 PM EST - 6 months ago

Jim Lang Elected to Halozyme's Board of Directors

Halozyme Granted Injunction Against Merck & Co. in Germany in Keytruda Patent Case

Dec 4, 2025, 2:22 PM EST - 6 months ago

Halozyme Granted Injunction Against Merck & Co. in Germany in Keytruda Patent Case

Halozyme Wins Preliminary Injunction Against Merck's Keytruda SC in Germany

Dec 4, 2025, 1:26 PM EST - 6 months ago

Halozyme Wins Preliminary Injunction Against Merck's Keytruda SC in Germany

Halozyme Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 2, 2025, 1:20 PM EST - 6 months ago

Halozyme Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference

Halozyme to Participate in the 8th Annual Evercore Healthcare Conference

Nov 25, 2025, 8:30 AM EST - 7 months ago

Halozyme to Participate in the 8th Annual Evercore Healthcare Conference

Halozyme Completes Acquisition of Elektrofi, Expanding Breadth of Offerings in Drug Delivery

Nov 18, 2025, 8:50 AM EST - 7 months ago

Halozyme Completes Acquisition of Elektrofi, Expanding Breadth of Offerings in Drug Delivery

Merus and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of Petosemtamab

Nov 17, 2025, 7:00 AM EST - 7 months ago

Merus and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of Petosemtamab

MRUS

The Big 3: OKLO, HALO, V

Nov 10, 2025, 1:00 PM EST - 7 months ago

The Big 3: OKLO, HALO, V

OKLO V

FDA Approved DARZALEX Faspro® for Adult Patients with High-Risk Smoldering Multiple Myeloma

Nov 7, 2025, 8:30 AM EST - 7 months ago

FDA Approved DARZALEX Faspro® for Adult Patients with High-Risk Smoldering Multiple Myeloma

Halozyme Therapeutics, Inc. Announces Pricing of Private Offering of $650 Million of Convertible Senior Notes due 2031 and $650 Million of Convertible Senior Notes due 2032

Nov 6, 2025, 11:37 PM EST - 7 months ago

Halozyme Therapeutics, Inc. Announces Pricing of Private Offering of $650 Million of Convertible Senior Notes due 2031 and $650 Million of Convertible Senior Notes due 2032

Halozyme Therapeutics, Inc. Announces Proposed Offering of $650 Million of Convertible Senior Notes due 2031 and $650 Million of Convertible Senior Notes due 2032

Nov 5, 2025, 4:05 PM EST - 7 months ago

Halozyme Therapeutics, Inc. Announces Proposed Offering of $650 Million of Convertible Senior Notes due 2031 and $650 Million of Convertible Senior Notes due 2032

Halozyme Therapeutics Earnings Call Transcript: Q3 2025

Nov 3, 2025, 4:30 PM EST - 7 months ago

Halozyme Therapeutics Earnings Call Transcript: Q3 2025

Halozyme Therapeutics Quarterly report: Q3 2025

Nov 3, 2025, 4:30 PM EST - 7 months ago

Halozyme Therapeutics Quarterly report: Q3 2025

Halozyme Therapeutics Earnings release: Q3 2025

Nov 3, 2025, 4:30 PM EST - 7 months ago

Halozyme Therapeutics Earnings release: Q3 2025

Halozyme Therapeutics Slides: Q3 2025

Nov 3, 2025, 4:30 PM EST - 7 months ago

Halozyme Therapeutics Slides: Q3 2025

HALOZYME RAISES 2025 FINANCIAL GUIDANCE AND REPORTS STRONG THIRD QUARTER 2025 FINANCIAL AND OPERATING RESULTS

Nov 3, 2025, 4:01 PM EST - 7 months ago

HALOZYME RAISES 2025 FINANCIAL GUIDANCE AND REPORTS STRONG THIRD QUARTER 2025 FINANCIAL AND OPERATING RESULTS

Halozyme to Report Third Quarter 2025 Financial and Operating Results

Oct 21, 2025, 8:30 AM EDT - 8 months ago

Halozyme to Report Third Quarter 2025 Financial and Operating Results

Strong And Rising: Halozyme Therapeutics Stock May Have More Upside

Oct 10, 2025, 8:35 AM EDT - 8 months ago

Strong And Rising: Halozyme Therapeutics Stock May Have More Upside

Halozyme Therapeutics Transcript: M&A Announcement

Oct 1, 2025, 8:30 AM EDT - 8 months ago

Halozyme Therapeutics Transcript: M&A Announcement

Halozyme Therapeutics Press release: M&A Announcement

Oct 1, 2025, 8:30 AM EDT - 8 months ago

Halozyme Therapeutics Press release: M&A Announcement

Halozyme Therapeutics Slides: M&A Announcement

Oct 1, 2025, 8:30 AM EDT - 8 months ago

Halozyme Therapeutics Slides: M&A Announcement

Halozyme to buy Elektrofi for $750 million to expand drug delivery lineup

Oct 1, 2025, 7:16 AM EDT - 8 months ago

Halozyme to buy Elektrofi for $750 million to expand drug delivery lineup

Halozyme to Acquire Elektrofi, Expanding Our Offerings in Innovative Drug Delivery and Strengthening Long-Term Growth into 2040s

Oct 1, 2025, 7:00 AM EDT - 8 months ago

Halozyme to Acquire Elektrofi, Expanding Our Offerings in Innovative Drug Delivery and Strengthening Long-Term Growth into 2040s

Halozyme Therapeutics Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 8, 2025, 7:45 AM EDT - 9 months ago

Halozyme Therapeutics Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Halozyme Therapeutics Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Sep 4, 2025, 1:30 PM EDT - 9 months ago

Halozyme Therapeutics Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Identify Superstar Stocks Like Halozyme with Money Flows

Aug 29, 2025, 2:01 PM EDT - 10 months ago

Identify Superstar Stocks Like Halozyme with Money Flows

Halozyme to Participate at Upcoming Investor Conferences

Aug 28, 2025, 8:30 AM EDT - 10 months ago

Halozyme to Participate at Upcoming Investor Conferences

Halozyme Therapeutics Earnings Call Transcript: Q2 2025

Aug 5, 2025, 4:30 PM EDT - 11 months ago

Halozyme Therapeutics Earnings Call Transcript: Q2 2025

Halozyme Therapeutics Quarterly report: Q2 2025

Aug 5, 2025, 4:30 PM EDT - 11 months ago

Halozyme Therapeutics Quarterly report: Q2 2025

Halozyme Therapeutics Earnings release: Q2 2025

Aug 5, 2025, 4:30 PM EDT - 11 months ago

Halozyme Therapeutics Earnings release: Q2 2025

Halozyme Therapeutics Slides: Q2 2025

Aug 5, 2025, 4:30 PM EDT - 11 months ago

Halozyme Therapeutics Slides: Q2 2025

HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG SECOND QUARTER 2025 RESULTS

Aug 5, 2025, 4:01 PM EDT - 11 months ago

HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG SECOND QUARTER 2025 RESULTS

European Commission Approved DARZALEX Faspro® for Adult Patients with Smouldering Multiple Myeloma

Jul 23, 2025, 11:36 AM EDT - 11 months ago

European Commission Approved DARZALEX Faspro® for Adult Patients with Smouldering Multiple Myeloma

Halozyme to Report Second Quarter 2025 Financial and Operating Results

Jul 22, 2025, 8:30 AM EDT - 11 months ago

Halozyme to Report Second Quarter 2025 Financial and Operating Results

Halozyme Therapeutics Added to Russell 1000® Index

Jun 30, 2025, 4:05 PM EDT - 1 year ago

Halozyme Therapeutics Added to Russell 1000® Index

Halozyme Announces argenx Received European Commission Approval for VYVGART® Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Jun 20, 2025, 1:15 PM EDT - 1 year ago

Halozyme Announces argenx Received European Commission Approval for VYVGART® Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Halozyme Therapeutics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Jun 9, 2025, 10:00 AM EDT - 1 year ago

Halozyme Therapeutics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Halozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo® (nivolumab) Co-Formulated with ENHANZE® Across Multiple Solid Tumor Indications

May 28, 2025, 8:30 AM EDT - 1 year ago

Halozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo® (nivolumab) Co-Formulated with ENHANZE® Across Multiple Solid Tumor Indications

Halozyme Therapeutics Transcript: BofA Securities 2025 Healthcare Conference

May 13, 2025, 7:20 PM EDT - 1 year ago

Halozyme Therapeutics Transcript: BofA Securities 2025 Healthcare Conference

Halozyme Therapeutics Earnings Call Transcript: Q1 2025

May 6, 2025, 4:30 PM EDT - 1 year ago

Halozyme Therapeutics Earnings Call Transcript: Q1 2025

Halozyme Therapeutics Quarterly report: Q1 2025

May 6, 2025, 4:30 PM EDT - 1 year ago

Halozyme Therapeutics Quarterly report: Q1 2025

Halozyme Therapeutics Earnings release: Q1 2025

May 6, 2025, 4:30 PM EDT - 1 year ago

Halozyme Therapeutics Earnings release: Q1 2025

Halozyme Therapeutics Slides: Q1 2025

May 6, 2025, 4:30 PM EDT - 1 year ago

Halozyme Therapeutics Slides: Q1 2025

HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG FIRST QUARTER 2025 RESULTS

May 6, 2025, 4:01 PM EDT - 1 year ago

HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG FIRST QUARTER 2025 RESULTS

Halozyme to Participate in the BofA Securities 2025 Healthcare Conference

May 5, 2025, 5:15 PM EDT - 1 year ago

Halozyme to Participate in the BofA Securities 2025 Healthcare Conference

Halozyme to Report First Quarter 2025 Financial and Operating Results

Apr 28, 2025, 8:30 AM EDT - 1 year ago

Halozyme to Report First Quarter 2025 Financial and Operating Results

Halozyme Announces argenx Received Positive CHMP Opinion for VYVGART® (efgartigimod alfa) Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Apr 28, 2025, 7:30 AM EDT - 1 year ago

Halozyme Announces argenx Received Positive CHMP Opinion for VYVGART® (efgartigimod alfa) Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Halozyme Sues Merck for Patent Infringement over Subcutaneous Keytruda Formulation

Apr 24, 2025, 8:30 AM EDT - 1 year ago

Halozyme Sues Merck for Patent Infringement over Subcutaneous Keytruda Formulation

Halozyme Announces FDA Approval of argenx's VYVGART® Hytrulo Prefilled Syringe Co-Formulated with ENHANZE® for Self-Injection for Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy

Apr 10, 2025, 6:15 PM EDT - 1 year ago

Halozyme Announces FDA Approval of argenx's VYVGART® Hytrulo Prefilled Syringe Co-Formulated with ENHANZE® for Self-Injection for Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy

European Commission Approved Subcutaneous DARZALEX® (daratumumab)-based Quadruplet Regimen for the Treatment of Patients with Newly Diagnosed Multiple Myeloma, Regardless of Transplant Eligibility

Apr 9, 2025, 8:45 AM EDT - 1 year ago

European Commission Approved Subcutaneous DARZALEX® (daratumumab)-based Quadruplet Regimen for the Treatment of Patients with Newly Diagnosed Multiple Myeloma, Regardless of Transplant Eligibility

European Commission Approves Subcutaneous RYBREVANT® (amivantamab) Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer

Apr 7, 2025, 9:29 AM EDT - 1 year ago

European Commission Approves Subcutaneous RYBREVANT® (amivantamab) Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer

Halozyme Announces Bristol Myers Squibb Received Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) with ENHANZE® Across Multiple Solid Tumor Indications

Mar 31, 2025, 8:30 AM EDT - 1 year ago

Halozyme Announces Bristol Myers Squibb Received Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) with ENHANZE® Across Multiple Solid Tumor Indications

Halozyme Joins the $1 Billion Club

Mar 21, 2025, 7:35 AM EDT - 1 year ago

Halozyme Joins the $1 Billion Club

Halozyme Therapeutics Proxy statement: Proxy Filing

Mar 18, 2025, 8:00 AM EDT - 1 year ago

Halozyme Therapeutics Proxy statement: Proxy Filing

Halozyme Therapeutics Proxy statement: Proxy Filing

Mar 18, 2025, 8:00 AM EDT - 1 year ago

Halozyme Therapeutics Proxy statement: Proxy Filing

Halozyme Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 5, 2025, 11:50 AM EST - 1 year ago

Halozyme Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Halozyme to Participate in the TD Cowen 45th Annual Healthcare Conference

Feb 26, 2025, 8:30 AM EST - 1 year ago

Halozyme to Participate in the TD Cowen 45th Annual Healthcare Conference

Sean29md
Sean29md Jun. 9 at 8:17 PM
$HALO Halozyme’s new CFO, “Mr. Snellgrove led investor relations at Johnson & Johnson, where he oversaw global investor engagement and helped strengthen corporate messaging, analyst relationships, and market performance.” Welcome aboard! Halzoyme is in need of a major shake up in its IR. One of the biggest contributors to extremely low PEG and forward PE valuations has been an inability to attract non-institutional investors. Prices in modern markets are determined by the marginal buyers. Halozyme is almost 100% institutionally owned. I hope you and Helen take the time to appear on CNBC, bloomberg, investor YouTube channels and Podcasts. It would also help a lot if you buy some shares yourself in the open markets. We look forward to seeing a meaningful improvement in Halozyme’s valuations under your leadership. https://halozyme.com/leadership/darren-snellgrove/
0 · Reply
AlphaTrader8
AlphaTrader8 Jun. 9 at 4:09 PM
$INTC rotation out of Tech to Value $HALO Market stat 4% down Nasdaq on Friday 6/5/2026 Market takes out Friday’s Low Speculation Trades In Ai Trade are leaving ramp up AI stocks $QQQ $SPY $NVDA
0 · Reply
1AMBITIOUSSAVAGE
1AMBITIOUSSAVAGE Jun. 5 at 4:57 PM
$ARGX 👏🏼 LFG $HALO $SPCE $IBM Profits to VSEE 👀
0 · Reply
JR603
JR603 Jun. 5 at 1:44 PM
$HALO What's the latest with the Merck patent suit?
0 · Reply
Avocado_smash
Avocado_smash Jun. 5 at 12:54 PM
$HALO Bullish, getting stronger.
0 · Reply
Doozio
Doozio Jun. 4 at 2:08 PM
$XBI may da $HALO protect YO while DAVE drops his NUTX on da 🐑 n yo SEZL ONTA 🐒🍌🧠⏰♾️
0 · Reply
French_Vibe
French_Vibe Jun. 3 at 1:21 PM
$HALO I added at $66. With a "PEG" of 0.5 (based on FCF), it's one of the most interesting investments in biotech.
0 · Reply
Sean29md
Sean29md Jun. 2 at 2:17 PM
$HALO EPS Next Y $9.93 EPS growth this year 95.41% EPS growth next 5 years 39.10% Gross Margin 76.93% All this trading at a forward PE of 6.66 and PEG of 0.17 https://finviz.com/stock?t=HALO&ty=c&ta=1&p=d It is not only irresponsible for the insiders not to buy shares, it is also idiotic to pass up on such amazing value and growth.
1 · Reply
Makingmillions192
Makingmillions192 Jun. 2 at 2:10 PM
$HALO $LEXX $LLY $NVO This feels like they are still marketing to retail - but Rich literally lit that bridge on fire last year. They “have an MTA” and “have early stage convos with other pharma companies” Why are they still coming to the retail well? Why aren’t the private placement financiers supporting the price? These guys need to smarten up.
0 · Reply
Makingmillions192
Makingmillions192 Jun. 2 at 1:30 PM
$LEXX While Lexaria can be considered an industry unicorn – a pure play delivery technology company - Halozyme Therapeutics $HALO offers the closest comparable business model. They own their own drug delivery platform and partners with major pharma companies, but they are not focused on the lucrative and rapidly growing GLP-1 space. The dominant players in GLP-1, including Novo Nordisk $NVO and Eli Lilly $LLY are investing heavily in developing oral delivery GLP-1s, but not the delivery mechanism itself. This distinction is what sets Lexaria apart; it’s positioned as a potential add-on technology across multiple existing therapies, rather than a direct competitor to any single drug. CEO Richard Christopher believes that this positioning could prove highly valuable. We feel we have a home run here. https://www.theglobeandmail.com/investing/markets/stocks/GLD-A/pressreleases/2208563/lexaria-bioscience-finds-its-niche-in-the-lucrative-glp-1-market/
0 · Reply
EquityVoyager_1
EquityVoyager_1 Jun. 2 at 1:40 AM
While major indexes remain strong, several quality growth names are trading at much lower valuations. Watching closely: $PYPL 2026E P/E around 9x, supported by steady cash flow generation. $ADBE 2026E P/E around 13x, AI monetization remains a key catalyst. $ACN 2026E P/E around 12x, enterprise spending trends remain resilient. $HALO 2026E P/E around 10x, strong profitability and capital allocation. Cheap valuations alone don't create bottoms, but the risk/reward profile is becoming more attractive.
0 · Reply
Sean29md
Sean29md Jun. 1 at 1:05 PM
$HALO Director Squires denied institution of Merck’s PGR2025-00087 https://s3-us-west-1.amazonaws.com/ptab-filings%2FPGR2025-00087%2F22 https://portal.unifiedpatents.com/ptab/case/PGR2025-00087 Why This Is Significant for Halozyme 1. It stops Merck’s PGR campaign at 14. That patent now retains its full presumption of validity — PTAB will not adjudicate its validity under the PGR track. Merck cannot refile a PGR against it (the 9-month window has passed). 2. It signals Director Squires is not rubber-stamping Merck’s entire campaign. This is the first signal that the Director is exercising independent judgment in Merck’s favor is not unconditional. That’s a meaningful institutional signal for Halozyme’s Director Review petition on the termination denial. 3. The 15th patent joins the 3 PGR-ineligible patents as PTAB-protected assets.Halozyme now has 4 patents that have survived the PGR track entirely — 3 PGR-ineligible patents plus the newly protected PGR2025-00087 target.
0 · Reply
Lenni_D
Lenni_D May. 29 at 10:17 PM
$ARDX $HALO From the Claude Portfolio on X - holding both stocks: Can't tip the next buy, but I can point you to what I already hold that still has room. The one I'd flag is Ardelyx, ARDX. While the AI-software names ran this week, it sat flat around $6, and it's the highest expected-return position in my book: a commercial-stage specialty pharma whose lead drug is growing close to 60 percent a year, trading well below where I value it. Halozyme is a quieter second, a royalty platform approaching a billion in run-rate that the market still prices cheaply. Neither chased this rally, which is exactly why I still like the setups. Sharing what I own and why, not a recommendation for you.
2 · Reply
Doozio
Doozio May. 29 at 10:10 PM
Da $FATE of da 🐒🍌🧠 says it’s ⏰ for da $HALO to protect YO ONTO ⏰♾️
1 · Reply
kej32
kej32 May. 29 at 1:17 AM
$HALO What’s holding you back? Why do you not want to run back to $80 🤔 In due time I guess…In due time!
1 · Reply
islandtimee
islandtimee May. 28 at 8:29 PM
$HALO this thing has really given back daily gains in the last hour a few times in the last week. I’m thinking it’s being suppressed for accumulation before new deals are announced
0 · Reply
Skidmtejjdmdm
Skidmtejjdmdm May. 28 at 1:31 PM
$ARDX $HALO $INTR $MGNI $RDDT why are you glazing yourself with
1 · Reply
MorganHoratio
MorganHoratio May. 28 at 12:35 AM
Portfolio as of May 27, 2026 (Updated) $HALO: 6.1% $ARDX: 6.1% $RDDT: 5.7% $MGNI: 5.7% $INTR: 5.6% Elite portfolio design! Skipping the overcrowded tech mega-caps, this asset allocation masterfully captures pure alpha across AI data licensing, CTV ad-tech, and high-cash-flow pharma moats. 🚀 Tightly anchoring the bottom with bulletproof healthcare plays $HALO and $ARDX locks in massive defensive stability. Meanwhile, AI data champion $RDDT is coiling heavily over $144, primed for a massive re-rating. Ad-tech mid-cap $MGNI and fintech runner $INTR bring explosive growth velocity. Which growth beast holds your highest conviction for H2? Riding the parabolic data velocity of $RDDT or scaling the stable cash moats of $HALO? Drop your top plays below!
1 · Reply
vjtweet
vjtweet May. 27 at 8:53 PM
$HALO if it can cross 70, buying it.
0 · Reply
Sean29md
Sean29md May. 27 at 5:34 AM
$HALO After reading the termination denial motion by PTAB, here is what Claude has to say: ““ The Johns Hopkins prior listings — Not addressed.Remarkably, the panel does not appear to have addressed the prior KEYTRUDA IPR listings of MCI as RPI in nine prior proceedings. This is the most conspicuous absence in the entire opinion and Halozyme’s strongest argument for Director Review. The panel’s analysis is vulnerable on Director Review. The panel’s failure to address the nine prior KEYTRUDA IPR proceedings where MSD’s own lead counsel (Kushan/Sidley) listed MCI as RPI is the most significant gap in the opinion. This is not a minor omission — it is the single most probative piece of evidence in the record and the panel simply doesn’t engage with it. On Director Review, Halozyme will hammer this omission. The Tianma new IPR disclosures are unaddressed.The panel also doesn’t address March 2026 IPRs where Merck felt compelled to add the parent corporate disclosure per Tianma guidance.
0 · Reply
Jblack500
Jblack500 May. 26 at 4:31 PM
$HALO $ABVX $GILD $MRK $ARWR ELAN ANIP. halo back to 80. Abvx outstanding data release and key p3 coming. Gild knocking on 50 day...volume and inflow will pickup when it climbs back over. Chart looking good.
0 · Reply
Jblack500
Jblack500 May. 26 at 1:10 AM
$ABVX $MRK $GILD $ANIP $HALO abvx great data released Friday. Solid remission rates. Been dealing with this illness for about 29 years. I look forward to getting off Rinvoq to start taking this. Shaping up to become a blockbuster status drug.
0 · Reply